Press-release for stocks related to events

Prices are updated after-hours

for tags : Events

save search

Two Clinical Trials Identify a Better Way to Target Appropriate Antibiotics for Patients Hospitalized With Pneumonia or Urinary Tract Infection
Published: 2024-04-19 (Crawled : 22:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320

Communications

| Email alert Add to watchlist
infection antibiotics trials for

Henry Schein Supports The ‘Carry The Load’ Memorial May Campaign For Third Consecutive Year
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
HSIC | $70.87 1.29% 1.27% 770K

Distribution Services

| -2.7% | O: -2.7% H: 0.0% C: 0.0%
year for

Mirion Announces Earnings Release and Conference Call Date for First Quarter 2024
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
MIR | $10.98 1.67% 0.0% 1.5M

| 1.44% | O: 0.96% H: 1.71% C: 0.48%
first conference for

Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
TARO | $42.25 0.14% 0.0% 17K

Health Technology

| 0.48% | O: 0.19% H: 0.28% C: 0.0%
approval for meeting

AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
Published: 2024-04-12 (Crawled : 13:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M

Health Technology

| -1.41% | O: -1.92% H: 0.0% C: 0.0%
qulipta abbvie treatment for migraine

Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy on May 23, 2024
Published: 2024-04-10 (Crawled : 11:00) - biospace.com/
TBPH | $9.35 1.63% 1.6% 430K

Health Technology

| 0.42% | O: -1.37% H: 2.14% C: 2.03%
treatment system for key potential

CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
Published: 2024-04-09 (Crawled : 13:00) - biospace.com/
CDNA | $8.32 3.1% 3.0% 500K

Health Technology

| -17.63% | O: 0.63% H: 5.84% C: 3.75%
lung international for meeting heart

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-05 (Crawled : 14:30) - biospace.com/
IMNM | $15.5 -9.78% -10.84% 2.1M

Health Technology

| -15.2% | O: -0.44% H: 3.37% C: 0.45%
im-3050 association cancer research preclinical for meeting therapy

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
Published: 2024-04-05 (Crawled : 12:30) - biospace.com/
NVCR | $12.09 0.33% 0.33% 850K

Health Technology

| -17.86% | O: -4.16% H: 1.07% C: -2.28%
association cancer pancreatic tumor research preclinical for meeting

Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
Published: 2024-04-02 (Crawled : 22:00) - biospace.com/
MIRM | News | $23.83 1.1% 1.09% 340K

Health Technology

| -7.39% | O: -1.3% H: 0.7% C: 0.36%
pruritus positive livmarli

Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research
Published: 2024-04-02 (Crawled : 12:30) - biospace.com/
LH M | $201.48 1.02% 0.0% 770K

Health Services

| -7.57% | O: -0.1% H: 0.01% C: -1.94%
precision association cancer research meeting

Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024
Published: 2024-04-01 (Crawled : 22:00) - biospace.com/
ALPN | $64.535 0.16% 0.16% 4M

Health Technology

| 62.64% | O: -0.83% H: 2.52% C: 2.31%
nephropathy congress world sciences

Biond Biologics Announces Presentation of BND-35, a Novel Anti-ILT3 Antibody for Remodeling the Tumor Microenvironment, at the American Association for Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-03-26 (Crawled : 20:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -5.72% | O: 1.93% H: 0.0% C: 0.0%
bnd-35 antibody association presentation cancer tumor research meeting

Translational Vision Science and Technology Journal Publishes RadiusXR's NOVA Clinical Trial, Demonstrating Industry-Leading Accuracy and Innovation in Visual Field Testing for Virtual Reality Perimetry
Published: 2024-03-25 (Crawled : 00:00) - biospace.com/
GKOS | $96.5 1.44% 0.0% 700K

Health Technology

| 10.0% | O: 0.73% H: 2.38% C: 0.0%
innovation vision technology

Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
Published: 2024-03-25 (Crawled : 13:30) - biospace.com/
ARWR | $22.33 -1.24% -1.25% 960K

Health Technology

| -13.01% | O: 0.37% H: 2.34% C: 2.12%
presentation pharmaceuticals program

Exscientia Business and Financial Update for the Full Year 2023
Published: 2024-03-21 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -2.29% | O: 0.14% H: 0.24% C: 0.24%
EXAI | $4.24 -2.75% -2.83% 370K

| -36.44% | O: -3.35% H: 0.0% C: -7.39%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -3.83% | O: 0.3% H: 0.0% C: 0.0%
business year update financial

LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
Published: 2024-03-20 (Crawled : 19:00) - biospace.com/
LIVN | $52.31 -0.85% -0.86% 430K

Health Technology

| 3.04% | O: 1.81% H: 11.57% C: 10.5%
success positive trial study

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
Published: 2024-03-19 (Crawled : 15:00) - biospace.com/
SONN | $1.84 3.96% 3.8% 22K

Health Technology

| -21.68% | O: 0.44% H: 2.52% C: -3.96%
son-080 preclinical meeting

BMS’s Breyanzi Becomes First CAR-T Therapy for Two Types of Leukemia
Published: 2024-03-15 (Crawled : 12:30) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M

Health Technology